Britannia Pharmaceuticals Ltd: Phase 3 TOLEDO Study Shows Apomorphine Infusion Provides Effective Relief of Persistent Motor Fluctuations in Parkinson#s Disease (PD) Patients Whose Symptoms are Uncontrolled With Oral Medication

Food and Healthcare Press Releases Monday August 6, 2018 11:25
LONDON--6 Aug--PRNewswire/InfoQuest
Britannia Pharmaceuticals Ltd has announced publication of the results of the double-blind phase of the TOLEDO study in Lancet Neurology[1].

Treatment with APO-go(R)/MOVAPO(R) (apomorphine) subcutaneous infusion for 12 weeks gave significantly greater reductions in OFF time (periods when PD medications don't work) from baseline compared with placebo: -2.47 h/day versus -0.58 h/day, respectively - a treatment difference of almost 2 hours (p=0.0025) and double the change in OFF time recognised as meaningful to PD patients. These reductions were seen in the first week of treatment with APO-go(R)/MOVAPO(R) infusion.

Compared with placebo, significantly greater increases in ON time (periods with good motor control) without troublesome dyskinesia - 'good' ON time - from baseline were observed with APO-go(R)/MOVAPO(R) infusion: 2-77 h/day versus 0-80 h/day, respectively (p=0-0008), and patients could also reduce the dosage and number of administrations of concomitant oral PD medications significantly (p=0.0014).

APO-go(R)/MOVAPO[(R)/] infusion is an established therapy for PD, a disease characterised by progressive degeneration of dopamine-containing neurons in the brain, resulting in loss of motor control. TOLEDO is the first multicentre, randomised, double-blind trial to investigate its efficacy and safety in PD and was undertaken in 107 patients from 23 hospitals in 7 countries whose symptoms were uncontrolled despite taking multiple medications.

Clinical improvements were reflected in patients' assessment of treatment: significantly more APO-go(R)/ MOVAPO(R) infusion patients rated themselves as 'improved' (71%) versus placebo (18%; p<0.0001).
Professor Regina Katzenschlager, lead investigator of TOLEDO, commented:

"TOLEDO is an important addition to our knowledge, providing Level 1 evidence for the first time and confirming previous observational studies. Apomorphine infusion is effective and well tolerated by patients experiencing debilitating treatment response fluctuations despite optimised treatment."

Professor Andrew Lees, an investigator in the pivotal clinical trial that led to apomorphine being licensed for PD treatment in the UK, added:
"We hope the positive results of the TOLEDO study will help ensure apomorphine infusion, which is delivered using a small, ambulatory mini-pump, is incorporated into national PD treatment guidelines."
The TOLEDO study is sponsored by Britannia Pharmaceuticals Ltd., part of the STADA Arzneimittel AG group of companies and manufacturer of apomorphine products.
Founded in 1982, Britannia Pharmaceuticals Limited is a pharmaceutical company based in Reading, UK, specialising in the neurology market.
Britannia is owned by Frankfurt-based STADA Arzneimittel AG.

APO-go(R) products are marketed in the UK by Britannia Pharmaceuticals Ltd and transferred with the acquisition of Britannia into the STADA portfolio in 2007. APO-go(R) products are marketed outside the UK through own affiliates and licensing partners.

For information about:
Britannia Pharmaceuticals Ltd:
http://www.britannia-pharm.com
TOLEDO study:
https://www.clinicaltrials.gov/ct2/show/NCT02006121?term=NCT02006121&rank=1
For the APO-go(R) infusion SmPC:
https://www.medicines.org.uk/emc/product/3908/smpc
[1]Katzenschlager R, et al. Lancet Neurology, 2018. Published online July 25, 2018   http://dx.doi.org/10.1016/S1474-4422(18)30239-4
Source: Britannia Pharmaceuticals Ltd

Latest Press Release

Future Health Index, Commissioned by Philips, Identifies Key Recommendations for Better Health Information Exchange to Drive Value in Healthcare

Royal Philips (NYSE: PHG) (AEX: PHIA), a global leader in health technology, today released a new Future Health Index (FHI) report " Moving data to the heart of health systems: Increasing vital technology adoption to make value-based healthcare a reality...

PULSUS Group collaborates with Anbu Kochi to Contribute towards Kerala Flood Victims

In a humanitarian effort, PULSUS Group - in collaboration with Anbu Kochi - is responding to the calamity of the recent, unprecedented floods in the Indian state of Kerala by providing contributions to aid relief and rehabilitation measures. PULSUS Group...

Menarini Ricerche Announces New Positive Results in Acute Myeloid Leukemia Cell Lines for MEN1112/OBT357 at the 60th Annual SIC Meeting

Menarini Ricerche will present tomorrow, September 20th, at the 60th Annual Meeting of the Italian Cancer Society (SIC), new preclinical data showing that pre-treatment with 5-Azacytidine and Decitabine enhances the Antibody-dependent cellular...

Experts Call for Improved Identification of #High Burden# Rosacea Patients in Everyday Practice

- Additional analysis of global survey data reveals quality of life is impacted by several factors extending beyond severity of rosacea alone Additional analysis of a global survey conducted and presented earlier this year, as an expert-authored report...

BookDoc collaborates with Chow Tai Fook: Get more rewards by staying active together with Chow Tai Fook

Chow Tai Fook is collaborating with BookDoc, the largest integrated healthcare app in Southeast Asia by healthcare network in giving more rewards to BookDoc users for maintaining an active healthy lifestyle. Users can now enjoy discounts and redeem...

Related Topics